

Michigan Pharmacy and Therapeutics Committee
Meeting of March 3, 2009
DRAFT DRAFT DRAFT Minutes DRAFT DRAFT DRAFT

Introductions:

Committee members present: Drs. Fiechtner, Dake, Thill, Dorfman, Perri, Bradley, Dillon
State staff present: Drs. Eggleston, Mattarella; Trish O'Keefe, Helen Walley
First Health staff present: Annette Paul, RPh

Approval of Minutes of December 2, 2008 Meeting

The minutes were approved as posted

New Drug Reviews:

Following presentation and review of the monographs, the Committee recommended to the Department the following:

Alvesco: add to the Michigan Pharmaceutical Product List (MPPL) and to the Preferred Drug List (PDL) class of Inhaled Glucocorticoids with prior authorization

Banzel: add to the MPPL

Cinryze: add to the MPPL

Mozobil: add to the MPPL

Line Extensions:

The Committee recommended to the Department

Stavzor: add to the MPPL

Lidocort Gel Kit: add to the MPPL with prior authorization

Keppra XR: add to the MPPL

Review of Cardiac Classes:

Following presentation of the Workgroup recommendations, the Committee recommended to the Department:

ACE Inhibitors: no changes to the current classification of drugs

Antihypertensive Combinations: ACEI-CCB: no changes to the current classification of Lotrel and Tarka; remove Lexxel from the list as it is no longer marketed

Antihypertensive Combinations ARB-CCB: no changes to the current classification of drugs

Angiotensin Receptor Antagonists: no changes to the current classification of drugs

Direct Renin Inhibitors: no changes to the current classification of Tekturna

Beta Blockers: no changes to the current classification of drugs

Calcium Channel Blockers-Dihydropyridine: no changes to the current classification of drugs

Calcium Channel Blockers-Non-dihydropyridine: no changes to the current classification of drugs

Lipotropic-Antihypertensive Combination: no changes to Caduet
Lipotropics-Non Statins: Fibrin Acid Derivatives: no changes to the current classification of drugs
Lipotropics-Non-Statins: no changes to the current classification of drugs
Lipotropics: Statins: no changes to the current classification of drugs
Lipotropics: Niacin derivatives: no changes to the current classification of drugs
Lipotropics; Other: no changes to the current classification of drugs

Public Comment:

The following persons made comment to the Committee:

H. Levy, ViroPharma, Cinryze

H. Quinones, PhD, AstraZeneca, Symbicort

K. Patel, PharmD, Schering-Plough, Asmanex, Nasonex, Proventil HFA

G. Stein, PharmD, Pfizer, Zyvox

G. Rigoni, PharmD, Abbott, Trilipix

E. Pitting, PharmD, Roche, Pegasys

C. Sproles, PharmD, Sepracor, Alvesco

The next meeting of the Committee is Tuesday, June 2, 2009